Cognitive Issues, Supplements / 28.11.2024
How Nootropics Work: A Beginner’s Guide to Cognitive Enhancement
Editor's note: Most Nootropics are not FDA tested or approved.
Supplements, including those sold as cognitive enhancers, may have side effects.
Please do not take nootropic medications or supplements without discussing with your health care provider first.
Have you ever wished for a way to sharpen your focus, improve your memory, or simply stay mentally clear throughout the day? Nootropics, often referred to as "cognitive enhancers," might be the solution you've been curious about. These supplements are gaining popularity among students, professionals, and anyone looking for that extra edge in mental performance. But how exactly do they work, and are they right for you?
[caption id="attachment_65164" align="aligncenter" width="500"]
Photo by emre keshavarz[/caption]
What Are Nootropics?
Nootropics are substances—either natural or synthetic—that are designed to enhance cognitive functions like memory, creativity, and focus.
Some of these might be things you’re already familiar with, like caffeine, while others are lesser-known compounds or herbal extracts.
A defining feature of nootropics from the likes of Simply Nootropics is that they are thought to support brain function without causing significant side effects. They’re not about forcing your brain into overdrive but rather optimising its natural processes.
Photo by emre keshavarz[/caption]
What Are Nootropics?
Nootropics are substances—either natural or synthetic—that are designed to enhance cognitive functions like memory, creativity, and focus.
Some of these might be things you’re already familiar with, like caffeine, while others are lesser-known compounds or herbal extracts.
A defining feature of nootropics from the likes of Simply Nootropics is that they are thought to support brain function without causing significant side effects. They’re not about forcing your brain into overdrive but rather optimising its natural processes.
Dr. Yu Mengge[/caption]
Dr Yu Mengge
Research Fellow, Cancer & Stem Cell Biology Signature Research Programme
Duke-NUS Medical School
MedicalResearch.com: What is the background for this study?
Response: The background of this study is rooted in the observation that certain genetic variations among East Asian populations, notably the BIM deletion polymorphism (BDP), impact treatment outcomes in chronic myeloid leukaemia (CML).
Patients with the BDP show resistance to conventional treatments, specifically tyrosine kinase inhibitors like imatinib. This resistance stems from the variant's role in promoting cancer cell survival, which leads to more aggressive disease progression.
Dr. Hazen[/caption]
Stanley Hazen, MD, PhD
Chair, Cardiovascular & Metabolic Sciences
Lerner Research Institute
CoSection head, Preventive Cardiology & Cardiovascular Rehabilitation
Heart, Vascular and Thoracic Institute
Cleveland Clinic
MedicalResearch.com: What is the background for this study?
Response: One of the unique features of COVID is that in some subjects, there unfortunately appear to be long term adverse effects that can occur following resolution of the acute infection. These studies add to the growing body of data showing that COVID-19 infection can enhance risk for experiencing adverse cardiac events (heart attack, stroke, and death) over time.
Dr. Nas[/caption]
Dr Zeynep Nas Ph.D.
Postdoctoral Research Fellow
Department of Behavioural Science and Health
Institute of Epidemiology & Health Care
University College London
MedicalResearch.com: What is the background for this study?
Response: We were interested in why some children are more selective in their food intake and more reluctant to try new foods compared to those who are not. We investigated this question in a twin study, which compares identical twins (who share all of their genes) to non-identical twins (who share half) to understand the relative influence of genetics versus the environment in shaping individual differences in fussy eating.
Prof. Mihaylova[/caption]
Borislava Mihaylova, DPhil
Associate Professor & Senior Health Economist
Nuffield Department of Population Health, University of Oxford,
UK & Professor of Health Economics
Wolfson Institute of Population Health
Queen Mary University of London, UK
MedicalResearch.com: What is the background for this study?
Response: Despite high risks of heart disease and stroke in people over 70 years old and high need for preventive treatment such as statins, fewer older people use statins [compared to middle-aged people]. This, at least in part, is likely due to fewer older people, particularly those without previous heart attacks and strokes, included in the randomized studies of statin treatment. This has led to more limited evidence among them with larger uncertainty. Thus, we set to re-examine the value of statin treatment using the latest evidence and contemporary population data.